The study found that GC patients with TP53 mutations often exhibit poor responses to traditional adjuvant chemotherapy due to compromised DNA repair, cell cycle regulation, and apoptosis, leading to chemoresistance. The gene discussed is TP53; the disease is gastric cancer.